<?xml version="1.0" encoding="UTF-8"?>
<fig id="fig3">
 <label>Fig. 3</label>
 <caption>
  <p>Antiviral activities of the best three compounds as detected by IPMA, NSC345647 (A), NSC87511 (B), and NSC343256 (C). Lopinavir (D), an HIV-protease inhibitor, was included as a positive drug control. Three controls for each compound (FIPV infection without the compound treatment, FIPV ± Tx; no infection with compound, -FIPV/+Tx; no infection without compound, -FIPV/-Tx) are presented on the upper panel. The three-antiviral cell-based conditions; pre-viral entry, post-viral entry, and prophylaxis activities are presented as described in the text.</p>
 </caption>
 <alt-text id="alttext0040">Fig. 3</alt-text>
 <graphic xlink:href="gr3_lrg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
